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Failureofoligodendrocyteprecursor cell (OPC)differentiationhasbeenrecognizedas the leadingcause for the failureofmyelin regeneration in
diseases such asmultiple sclerosis (MS). One explanation for the failure of OPC differentiation inMS is the presence of inhibitorymolecules in
demyelinated lesions.So faronlya fewinhibitorysubstrateshavebeen identified inMSlesions.Semaphorin3A(Sema3A),asecretedmemberof
the semaphorin family, can act as repulsive guidance cue for neuronal and glial cells in the CNS. Recent studies suggest that Sema3A is also
expressed inactiveMS lesions.However, the implicationofSema3Aexpression inMS lesions remainsunclearasOPCsarecommonlypresent in
chronic demyelinated lesions. In the present studywe identify Sema3A as a potent, selective, and reversible inhibitor of OPC differentiation in
vitro. Furthermore, we show that administration of Sema3A into demyelinating lesions in the rat CNS results in a failure of remyelination. Our
results imply an important role for Sema3A in the differentiation block occurring inMS lesions.
Introduction
Chronic demyelination in multiple sclerosis (MS) represents a
significant challenge to clinical neurology. Chronic demyelina-
tion results from failed attempts of myelin regeneration, or
“remyelination,” and leaves axons chronically denuded. As de-
myelinated axons are prone to injury (Nguyen et al., 2009) and
degeneration (Irvine and Blakemore, 2008), chronic demyelina-
tion is likely to significantly contribute to the clinical burden of
the disease.
Although the mechanisms involved in CNS remyelination
have been an intense focus of research, no treatments currently
exist that are able to promote myelin regeneration in clinical
disease. Remyelination in the CNS is mediated by a multipotent
adult stem-precursor cell population commonly referred to as
oligodendrocyte precursor cells (OPCs) (Dubois-Dalcq et al.,
2008; Franklin and ffrench-Constant, 2008). Successful remyeli-
nation relies on the recruitment of OPCs into areas of demyeli-
nation, their subsequent engagement of denuded axons and their
differentiation into mature oligodendrocytes.
Systematic assessment of MS lesions revealed that in most
chronic demyelinated lesionsOPCs are present (Kuhlmann et al.,
2008). Therefore the processes involved in OPC differentiation
seem to be more vulnerable than the processes involved in OPC
recruitment. In contrast to the clinical situation, experimental
studies have demonstrated that OPC differentiation occurs effi-
ciently in animal models of CNS remyelination. To explain the dis-
crepancies between the efficiency of OPC differentiation and
remyelination in experimental models and human disease, the con-
cept has emerged that MS lesions contain specific OPC diffe-
rentiation-inhibiting factors. So far anumberofOPCdifferentiation
inhibitors have been indentified in MS lesions (Wang et al., 1998;
Charles et al., 2002; John et al., 2002; Back et al., 2005; Fancy et al.,
2009; Nakahara et al., 2009). Adding to the group of inhibitors, we
were recently able to show that unknown proteins in myelin debris
(myelin-associated inhibitors) that accumulate as a consequence of
demyelination also inhibit remyelination by inhibiting OPC differ-
entiation (Kotter et al., 2006; Syed et al., 2008; Baer et al., 2009).
Semaphorins comprise a large family of molecular guidance
cues, defined by their semaphorin (Sema) domain and further
distinguished by distinct protein domains including thrombos-
pondin, Ig-like, and basic C-terminal domains. Little is known
about the role of semaphorins in the context of oligodendrocyte
biology. A previous study has associated Sema3A with negative
guidance cues acting on OPCmigration and diverting OPC pro-
cesses (Spassky et al., 2002). Furthermore, a recent postmortem
study investigated the expression of Sema3A in brains of individ-
uals suffering from MS and controls (Williams et al., 2007).
While control white matter and chronicMS lesions did not show
any evidence of Sema3A expression, an upregulation of Sema
transcripts was detected in active MS lesions. OPCs present in
active MS lesions expressed the Sema receptor neuropilin-1
(NP-1) indicating that OPCs become reactive to Sema3A. How-
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ever, Sema3A expression in demyelinated lesions did not prevent
the recruitment of OPCs.
The experiments summarized in the present article identify
Sema3A as a regulator of OPCs in vitrowhose presence induces a
potent, selective, and reversible inhibition of OPC differentia-
tion. Furthermore, we tested the hypothesis that Sema3A inhibits
CNS remyelination by administering recombinant Sema3A into
experimentally demyelinated lesions. Our data indicate that the
presence of Sema3A is able to induce a failure of CNS remyelina-
tion without affecting the presence of OPCs.
Materials andMethods
Preparation of primaryOPC cultures. PrimaryOPC cultures were isolated
fromneonatal SpragueDawley (postnatal day 0–2) rat forebrains follow-
ing a standard protocol (Baer et al., 2009).Differentiationwas induced by
Sato’s medium supplemented with 0.5% FCS. Only cultures with94%
purity were used.
In preliminary experiments that have lead to the present study, OPCs
were cultured in medium conditioned by Sema3A-AP (alkaline phos-
phatase)-expressing Hek 293 cells (kindly provided by Prof. James Fawcett,
University of Cambridge, Cambridge, UK); the Sema3A-AP construct is
described by Giger et al. (1998) and was a generous gift from Prof. Joost
Verhaagen, Netherlands Institute for Neuroscience (Amsterdam, The
Netherlands). OPCs react to Sema3A-AP at the concentrations com-
monly used (supplemental Fig. 1a, available at www.jneurosci.org as
supplemental material) (Schlomann et al., 2009). OPCs react to com-
mercially available recombinant Sema3A-Fc (R&D Systems) at corre-
sponding concentrations (5 g/mlN44.24 nM). For the purpose of
limiting any confounding factors all subsequent experiments were per-
formed using recombinant Sema3A-Fc from the commercial source.
Thus, either Sema3A substrates were prepared by incubation of poly-L-
lysine (PLL)-coated slides with recombinant Sema3A-Fc or, alterna-
tively, recombinant Sema3A-Fc was added to Sato’s differentiation
medium. To assess whether the effects of Sema3A are reversible cells were
first cultured in Sema3A containing differentiation medium. After 24 h
themediumwas replaced with Sema3A-free differentiationmedium and
the cells were cultured for further 48 h (Fig. 1i).
Immunocytochemical analysis. OPCs were seeded onto PLL- or
Sema3A-coated 8-well chamber slides (2  104 cells/well). Following
differentiation (48 h), cells were stained withO4 (1:100; Calbiochem;) or
A2B5 antibodies (1:100;MilliporeCorporation; Cy3-conjugated second-
ary antibody 1:100 dilution, Jackson ImmunoResearch) (Syed et al.,
2008; Baer et al., 2009). To assess OPC differentiation the percentage of
O4 cells to 100 4,6-diamidino-2-phenylindole dihydrochloride-
stained nuclei per experiment for each condition in randomly selected
Figure1. a–c,OPCsplatedonSema3Asubstrates(protein/cm2)displayaconcentration-dependentdownregulationofO4expressionafter2dofcultureindifferentiationmedium.d,Furthermore,RT-qPCR
demonstrates that Sema3A inhibits the expression of MBPmRNA. e–g, The presence of Sema3A also induces a reduction of the complexity of OPC processes and an increase of earlier morphological stages
compared with OPCs plated on control substrate (I, mono/bipolar; II, primary; III, secondary; IV, membranous branches). h, Sema3A selectively affects OPC differentiation as no differences in cell death were
detectedbyactivatedcaspase-3staining. i–l, The inhibitionofOPCdifferentiationbySema3Ais reversible.Whereas themajorityofOPCs indifferentiationmediumareO4-positiveafter24h(Diff/24h),addition
ofSema3A(S3A/24h) inhibitsO4expression.Cells remained inhibitedas longasSema3Awaspresent in themedium(S3A/72h). In contrast, 48h following replacementwithnon-Sema3A-containingmedium
OPCs (Sema3A/24 h‹Diff/48 h “withdrawal”) display O4 immunoreactivity corresponding to levels of control cells (Diff/24 h andDiff/72 h). Conversely, replacement of differentiationmediumwith Sema3A-
containingmediumafter 24 h results in an inhibition of OPCdifferentiation (Diff/24‹Sema3A/48h). Scale bar, 30m. In this and subsequent figures, error bars represent SEM.
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eye fields was determined. To assess the morphological phenotype of
OPCs, 100 A2B5 stained cells were categorized as follows: stage I:
mono/bipolar; stage II: multipolar, primary branched; stage III: multi-
polar, secondary branched; stage IV: secondary branched cells with
membranous processes. At least three independent experiments were
conducted. Neuropilin-1 (NP-1) expression by cultured OPCs was as-
sessed usingNP-1 (1:200; Abcam; Alexa Fluor 488-conjugated secondary
antibody 1:500 dilution) and A2B5 (1:100; Millipore Corporation; Alexa
Fluor 548-conjugated secondary antibody 1:500). Cells were visualized
on a LSM 5 Pascal confocal microscope (Zeiss).
Assessment of cell viability and apoptosis. Fragmented DNA was de-
tected by terminal deoxynucleotidyl transferase-mediated biotinylated
UTP nick end labeling (TUNEL) assay (Promega) and the percentage of
apoptotic nuclei was determined (Baer et al., 2009). To confirm that
Sema3A does not affect cell survival in addition to TUNEL assays the
percentage of active caspase-3-positive cells was determined (active
caspase-3 antibody, Abcam, 1:300; Alexa Fluor 488- or 548-conjugated
secondary antibody, Invitrogen, 1:300).
Quantitative reverse transcriptase PCR. Total RNA was extracted using
RNeasy Mini Kit (Qiagen). Quantitative PCR (qPCR) was conducted as
previously outlined (Baer et al., 2009) on an Applied Biosystems 7500HT
Fast Real-time PCR system. Values are represented as myelin basic pro-
tein (MBP)/2-microglobulin ratios. Triplicate measurements were
made on three biological replicates.
Induction of focal demyelination. All experiments were conducted in
accordance with animal welfare regulations of the German animal pro-
tection law, the state of Lower Saxony (Niedersa¨chsisches Landesamt fu¨r
Verbraucherschutz und Lebensmittelsicherheit (license: RKO_033/
2008) and Max Planck Institute guidelines.
Female Sprague Dawley rats (180–200 g) were anesthetized with ket-
amine (75 mg/kg) and xylazine (10 mg/kg) and positioned in a stereo-
tactic instrument (custommade). Demyelinationwas induced bilaterally
by stereotactic injection of ethidium bromide (0.01%, 4 l) into the
caudal cerebellar peduncle (CCP) (10.4mmcaudal,2.6mm lateral and
7.07 mm ventral to bregma) with slight modifications to the method
detailed previously (Kotter et al., 2006) (supplemental Fig. 2a, available
at www.jneurosci.org as supplemental material).
For continuous local delivery of proteins into demyelinated lesion, a 30
gaugemodifiedmouse osmotic pump connector cannulawith dummywire
(tubing length of 6.1mmbelow the cannula pedestal; Plastics One Inc.) was
placed at the same coordinates and attached to the skull (Loctite 454).
Infusion of Sema3A into demyelinated lesions.Ten days following lesion
induction osmotic pumps (0.5 l/h; 14 d, Alzet 2002, Durect Corpora-
tion) were filled with Sema3A (R&D Systems; 50 g/ml in PBS) or PBS
according to the manufacturers instructions. The surgical wound was
reopened, the dummy wire removed and the osmotic pumps were con-
nected and implanted subcutaneously. To verify efficient delivery of
Sema3A into the target area, a dye experiment was performed (supple-
mental Fig. 2b, available at www.jneurosci.org as supplementalmaterial).
To test whether Sema3A alters the appearance of normal white matter,
Sema3A was infused into naive CCPs. Sema3A neither affected the pres-
ence of myelin sheaths nor induced any other visible effects in normal
white matter (supplemental Fig. 2c, available at www.jneurosci.org as
supplemental material).
In situ hybridization. The expression of a number of marker mRNA
species in demyelinated lesions was examined by in situ hybridization
with digoxigenin-labeled cRNA probes. In situ hybridization probes for
macrophage scavenger receptor type B (MSR-B), platelet-derived growth
factor receptor- (PDGFR-),Nkx2.2, andproteolipidprotein (PLP)werea
gift fromProf. R. J.M. Franklin,University ofCambridge (Cambridge,UK).
The in situ hybridization probe for Sema3A was kindly provided by Prof. J.
Verhaagen, Netherlands Institute for Neuroscience.
Animalswere perfusedwith 4%paraformaldehyde (PFA) via the left ven-
tricle. The tissue was extracted, postfixed in 4%PFA, cryoprotected in 30%
sucrose and snap frozen. In situ hybridizations were conducted on cryostat
sections (15m) using established protocols (Kotter et al., 2006).
For two-color in situ hybridization (ISH), the sectionswere hybridized
with two riboprobes, one labeled with digoxigenin (DIG) and the second
with FITC. Transcripts of the DIG labeled probe were visualized with
AP-conjugated anti-DIG antibody and nitroblue tetrazolium/BCIP (5-
bromo-4-chloro-indoyl phosphate) (Roche), producing a dark blue de-
posit. Subsequently AP was inactivated by incubation in maleic acid
buffer (65°C, 30 min) and the FITC-labeled probe visualized with
AP-conjugated anti-FITC antibody and 2-(4-iodophenyl)-5-(4-nitrophenyl)-
3-phenyltetrazolium chloride/BCIP (Sigma-Aldrich), resulting in magenta
deposits.
Lesions were identified on digital images of solochrome cyanine-
stained sections, and the lesion area was determined using ImageJ 1.43b
(http://rsb.info.nih.gov/ij/). The same program was used to determine
the number of stained cells within the lesions on digitized adjacent sec-
tions. To rule out effects attributable to the size of the lesion, the density
of PLP-positive cells was assessed in the PBS group by linear regression
(GraphPad, Prism). The inclusion of lesions 0.4 mm2, which were
strongly populated with PLP-positive cells, resulted in a significant non-
zero slope indicating an effect of the lesion size on the cell density. This
may be explained by the fact that in small lesions recruitment of OPCs
and the clearance of myelin debris is more efficient and thus remyelina-
tion becomesmore efficient compared with larger lesions. No significant
correlation between the size of the lesion and the density of PLP-positive
cells was observed in lesions0.4 mm2 area. Consequently, only lesions
0.4 mm2 were included in the analysis.
Immunohistochemistry. Tissue was processed as for ISH. Sections were
incubated in sodium citrate (10 mM, microwave preheated), permeabil-
ized, and blocked with PBS, 5% serum 0.3% Triton X-100 (1 h, room
temperature), and incubated with primary antibody in PBS, 2% serum
(overnight, 4°C). For neuropilin-1 immunohistochemistry (IHC) the
permeabilization stepwas omitted. and the sections were blocked in PBS,
10% serum (1 h, room temperature) and incubated with primary anti-
body diluted in PBS, 2% serum (overnight, 4°C). Following a washing
step (PBS), sections were incubated with appropriate Alexa 488- or 594-
conjugated secondary antibodies (1:500, Invitrogen). Nuclei were visu-
alized with Hoechst 33342 and the slides mounted with Fluor Save
(Calbiochem). Images were acquired on a Confocal LSM 5 Pascal (Zeiss)
microscope.
The following antibodies were used: polyclonal anti-Olig-2 (1:1000;
Millipore), polyclonal anti-neuropilin-1 (NP1, 1:300; Abcam), poly-
clonal GFAP (1:500; Dako), monoclonal Nkx2.2 (1:300; Developmental
Studies Hybridoma Bank, University of Iowa, Iowa City, IA), monoclo-
nal CC1 (1:300; Calbiochem). For combinations of ISH with IHC the
ISH step was conducted first followed by IHC using the protocols pro-
vided (Arnett et al., 2004).
Histological analysis of remyelination. To assess the extent of remyeli-
nation tissue was fixed in 4% glutaraldehyde, osmicated and processed
into resin (TAAB Laboratories) (Kotter et al., 2006). Sections (1 m)
were stained with methylene blue and Azur-II. Remyelination was as-
sessed by rank analysis with researchers blind to experimental groups.
Lesions with the greatest extent of remyelination were assigned the high-
est rank value.
Electron microscopy.Ultrathin sections (50 nm) containing the lesions
were stained with aqueous 4% uranylacetate and lead citrate. The sec-
tions were visualized on an electron microscope (Leo EM912AB; Zeiss)
and images were taken using an on-axis 2048  2048 charge-coupled
device camera (Proscan, Schering).
Oil Red O staining.Oil Red O (Sigma) working solution was prepared
by adding 20 ml of H2O to 30 ml of 1% Oil Red O in isopropanol.
Sections were stained for 10 min then washed for 4 min and counter-
stained in Carrazi’s hematoxylin for 4 min. Following a 4 min wash in
H2O, the sections were differentiated in 0.5% aqueous hydrochloric acid
for 7 s and again washed in water for 10 min. Finally, the slides were
mounted using an aqueousmountingmedium. Representative images of
Oil Red O stained lesions were digitized and blindly ranked with the
highest staining density receiving the highest rank value.
Data analysis. Data were analyzed using GraphPad software (Prism).
Multiple group comparisons were conducted using one-way ANOVA
followed by Dunnett’s post test. To detect cellular differences between
Sema3A-treated and PBS-infused animals and for analysis of qPCR data
two-tailed Student’s t tests were conducted. For rank analysis a two-tailed
nonparametric Mann–Whitney test was used.
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Results
Sema3A induces a dose-dependent inhibition of
OPC differentiation
We set out to assess the effects of a number of proteins on OPC
differentiation that are known to act as lesion-associated inhibi-
tors of axon regeneration. For this purpose we used a well estab-
lished assay (Robinson and Miller, 1999; Baer et al., 2009) in
which the expression of O4 was assessed on primary OPCs cul-
tured on substrates prepared from various molecules as summa-
rized in Table 1 and by Syed et al. (2008). Of the molecules tested
only the presence of Sema3A resulted in a reduction of differen-
tiating O4-positive OPCs (Fig. 1a; supplemental Fig. 1a–c, avail-
able at www.jneurosci.org as supplemental material). The
inhibitory effect of Sema3A was confirmed in three independent
experiments assessing O4 antigeneity (n 3; one-way ANOVA:
p 0.0001; Dunnett’s post test PLL (93.67 1.202%) vs Sema3A
(2.5 g/cm2, 61.67  3.844%; 5 g/cm2, 48.33  3.180%, 10
g/cm2, 35.70  3.874%; p  0.05) and on the basis of quanti-
tative reverse transcriptase (RT)-PCR-based assessment of the
expression of MBPmRNA relative to 2-microglobulin (Fig. 1d;
n 3; PBS, 0.73 0.05967, Sema3A, 0.26 0.05967; t test, p
0.0051). Furthermore, the presence of Sema3AOPCs also induced a
reduction in the complexity of OPC processes (Fig. 1e–g).
To rule out that the decrease of O4 expression mediated by
Sema3A was a result of cell death or proliferation cleaved
caspase-3 staining (Fig. 1h), TUNEL assays (supplemental Fig.
1d, available at www.jneurosci.org as supplemental material),
and cell counts were conducted (data not shown). As neither
active caspase-3 staining [Fig. 1h; n  3, one-way ANOVA: p 
0.3422, Dunnett’s post test, PLL (12.48  1.982%) vs Sema3A
(2.5 g/cm2, 11.65  0.7112%; 5 g/cm2, 10.21  1.164%; 10
g/cm2, 15.67  3.277%: p  0.05) nor TUNEL assay (n  3,
one-way ANOVA: p  0.124, Dunnett’s post test PLL (14 
1.155%) vs Sema3A (2.5 g/cm2, 14.57  1.374%; 5 g/cm2,
23.00 8.021%; 10g/cm2, 27.00 3.464%): p 0.05] showed
significant differences, we concluded that Sema3A selectively in-
hibits the differentiation of OPCs into oligodendrocytes.
The differentiation block induced by Sema3A is reversible
To determine whether the inhibitory effect induced by Sema3A is
reversible, Sema3A was added to differentiation medium of pu-
rifiedOPC cultures. After 24 h one part of the cells were fixed and
stored for further analysis. The medium of the remaining cells
was replaced with either Sema3A-free or Sema3A-containing
medium and the cells cultured for further 48 h. Assessment of O4
immunoreactivity confirmed that O4 expression was inhibited as
long as Sema3A was present in the medium (Fig. 1i–l). However,
following removal of Sema3A (Sema3A/24 h‹Diff/48 h) the in-
hibition was lost and the cells were able to differentiate (n  3;
one-way ANOVA: p  0.0001, Dunnett’s post test Sema3A/24 h
(14  1.155%) vs control differentiation medium (Diff/24 h)
(95.59  0.9515%), Sema3A/24 h‹Diff/48 h (withdrawal)
(90.12  3.084%), and Diff/72 h (94.67  0.8819%); p  0.05;
Sema3A/24 h vs Diff/24‹Sema3A/48 h (36.83  6.022%), and
Sema3A/72 h (49.67 2.281%); p 0.05).
Assessment of the effects of Sema3A in demyelinating lesions
A recent postmortem study demonstrated that Sema3A is ex-
pressed in nonmyelinatingMS lesions at a phase, whichmight be
critical for the outcome of endogenous efforts of remyelination
(Williams et al., 2007). We therefore hypothesized that Sema3A
inhibits OPC differentiation in vivo and consequently impairs
CNS remyelination. To test this we adopted a well established
model of CNS remyelination based on stereotactic delivery of
Table 1. List of proteins tested for their role in OPC differentiation
Protein Biological function Cellular location
Myelin-associated glycoprotein (MAG) Member of the Ig superfamily binding sialic acid (Kelm et al., 1994; Crocker et al., 1998); one of several white matter inhibitors
of neurite outgrowth in vitro and axonal regeneration in vivo (Filbin, 2003); inhibits microtubule assembly by a Rho-kinase-
dependent mechanism (Mimura et al., 2006). Deletion of MAG induces a developmental delay in OPC differentiation and
myelin formation (Pernet et al., 2008).
Membrane
Nogo-A Myelin-associated neurite outgrowth inhibitor. Nogo-A plays a role both in the restriction of axonal regeneration after injury
and in structural plasticity in the CNS of higher vertebrates (Prinjha et al., 2000; Fournier et al., 2001). Deletion of Nogo-A
induces a developmental delay in OPC differentiation and myelin formation (Pernet et al., 2008).
Membrane
Oligodendrocyte myelin glycoprotein
(OMgp)
A glycosyl phosphatidyl inositol-linked protein and minor component of both CNS and PNS myelin. OMgp expression is also
found in cells extending processes to nodes of Ranvier that may prevent aberrant sprouting from the node (Huang et al.,
2005). OMgp may also exert antiproliferative effects on OPCs and induce OPC differentiation (Vourc’h and Andres, 2004)
Membrane
Brevican Highly abundant proteoglycan in normal brain (Yamaguchi, 2000).; contributes to the nonpermissive environment for axon
regeneration (Quaglia et al., 2008).
Extracellular matrix
Membrane
Secreted
Netrin-1 Major neuronal guidance cue (Serafini et al., 1994); can provide both attractive and repulsive cues to neurons, depending on
the receptors present and cellular context.
Extracellular matrix
Early studies have indicated that netrin-1 acts as chemorepellent for optic nerve-derived OPCs (Sugimoto et al., 2001). Simi-
larly, it has been shown that addition of netrin-1 to the medium is able to repel OPCs in transmigration assays as well as
negatively regulate OPC process formation during a time interval ranging from 30 min to 16 h following exposure (Jarjour et
al., 2003). However, the same group subsequently reported that netrin-1 does not affect the differentiation of immature or
mature OPCs in vitro (observation period, 24 h). Moreover, data included in our paper demonstrate that netrin-1 is able to
exert positive effects on process formation, branching, and myelin-like sheet formation (Rajasekharan et al., 2009). The
temporal switch from netrin-1-mediated chemorepulsion and process inhibition to process elaboration occurring in OPCs
was subsequently shown to be dependent on RhoA signaling (Rajasekharan et al., 2009). The present experiment assessed
the OPC response following 48 h of exposure to netrin-1 substrates and mirrors the results reported following prolonged
exposure to netrin-1 (24 h) (Rajasekharan et al. 2010; Rajasekharan et al., 2009).
Secreted
Myelin oligodendrocyte glycoprotein
(MOG)
Target antigen for the experimental autoimmune encephalitis (Lebar et al., 1986); present on the outermost lamellae of ma-
ture CNS myelin. Its late appearance during myelinogenesis suggests that it contributes to myelin maturation or mainte-
nance (Amor et al., 1994; Genain et al., 1999).
Membrane
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ethidium bromide into the CCP. In this model OPCs are re-
cruited into demyelinated areas within 5 d (Woodruff and
Franklin, 1999; Kotter et al., 2006). The first evidence of re-
myelination in this model can be observed 10 d following
lesion induction at the lesion border. To assess the effects of
Sema3A on remyelination Sema3A-Fc was stereotactically infused
fromday 10 post-lesion induction (supplemental Fig. 2a,b, available
at www.jneurosci.org as supplemental material). At 28 d the lesion
size was assessed. No significant changes in the lesion size were de-
tected between the groups (supplemental Fig. 3, available at www.
jneurosci.org as supplemental material).
Expression of NP-1 and Sema3A in CCP lesions
To confirm that OPCs are able to react to Sema3A the expression
of the Sema3A receptor NP-1 was assessed in purified OPC cul-
tures as well as in CCP lesions (Fig. 2). Colocalization of NP-1
Figure 2. a–d, Cultured OPCs express the Sema3A receptor NP-1. e–h, Apart from other cell types (outline arrowheads) NP-1 antigeneity was also detected on Nkx2.2-positive OPCs in 14 d
post-lesion induction (white arrowheads). i–m, Further cell types expressing NP-1 include astrocytes (white arrowhead; outline-arrowheads: non-GFAP-positive NP-1-expressing cells) (i–l ) and
osteopontin-mRNA-expressingmicroglia/macrophages (m). However, NP-1was only detected inmicroglia/macrophages expressingOPNat low levels (black arrowheads),whereas cells expressing
OPN at high levels did not express NP-1 (outline-arrowheads). In addition, the endogenous expression of Sema3Awas assessed 14 d post-lesion induction. n, Whereas low-olig-2-expressing OLCs
(black arrowheads) expressed Sema3A mRNA, Sema3A was not detected in high-olig-2-expressing OLCs (open arrowheads). o, GFAP-immunopositive astrocytes showed only weak expression of
Sema3AmRNA transcripts (black arrowheads).p, In contrast, OPN-mRNA-positivemicroglia/macrophages seemed a prominent source of Sema3A (black arrowheads). (Outline arrowheads inp,m,
Sema3A-expressing cells that did not coexpress GFAP or OPN, respectively.) Scale bar (in p): a–d, 20m; e–h, 8m; i–l, 8m;m–p, 30m.
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antigeneity and A2B5 in culture and the presence of NP-1/
Nkx2.2 cells in control lesions at 14 d confirmed that OPCs
express NP-1 both in vitro (Fig. 2a–d) and in vivo (Fig. 2e–h).
[Nkx2.2 is a transcription factor associated with early stages of
OPCdifferentiation and amarker ofOPC activation (Fancy et al.,
2004; Kotter et al., 2006).] Apart from OPCs, we also found evi-
dence of NP-1 expression by GFAP-positive astrocytes (Fig. 2l)
and by a subpopulation of osteopontin (OPN) mRNA-expre-
ssingmacrophages/microglia (Fig. 2m). NP-1-expressingmacro-
phages/microglia were smaller and expressedOPN at lower levels
than NP-1-negative macrophages/microglia, and thus NP-1 ex-
pression potentially is able to differentiate between cells at differ-
ent stages or from different origins.
To identify endogenous sources of Sema3A in native CCP
lesions combinations of in situ hybridization for Sema3A and
immunohistochemistry for Olig-2 (OPCs) and GFAP (astrocytes),
and double-in situ hybridizations for Sema3A andMSR-B (macro-
phages/microglia) were conducted.While Sema3A transcripts often
colocalized with oligodendrocyte lineage cells (OLCs) expressing
Olig-2 transcripts at low levels we were unable to detect Sema3A
expression in OLCs expressing Olig-2 at high levels with certainty.
Furthermore, Sema3A expression by GFAP-positive astrocytes and
OPN-positive macrophages was noted (Fig. 2n–p).
Sema3A infusion does not alter the macrophage response
Cells of the immune response and especiallymacrophages play an
important role in the process of remyelination (Kotter et al.,
2001). To assess whether Sema3A infusion alters the number of
macrophages within the lesion in situ hybridization for MSR-B
was conducted (Fig. 3a–d). Although it has been shown that
Sema3A is able to induce apoptosis in monocyte-derived macro-
phages (Ji et al., 2009), in the present experiment Sema3A did not
alter the presence of macrophages (10 d: n  10, 128.7  25.91
cells/mm2; Sema3A: n  7, 167.7  21.33 cells/mm2; PBS con-
trols: n 6, 135.3 27.13 cells/mm2).
In addition to the presence of macrophages we assessed the
phagocytic activity in the lesions on the basis of Oil RedO stained
neutral lipids (Fig. 3e–h) (Kotter et al., 2005).Whereas high levels
of Oil Red O staining were detected at day 10 (n 8, mean rank
value 13.63  0.5957) indicative of ongoing phagocytosis, no
differences between Sema3A-treated (n  5, mean rank value
5.83 1.493) and control lesions (n 6, mean rank value 5.8
1.158) were found 28 d post-lesion induction.
Sema3A infusion does not alter the presence of OPCs in
demyelinated lesions
OPCs in demyelinated lesions were visualized by in situ hybrid-
ization for PDGFR- (Fig. 4a–d) (Kotter et al., 2006). No differ-
ences were found between Sema3A-infused lesions (n  7;
155.8 10.10 cells/mm2), lesions before infusions at day 10 (n
11; 143.1  20.80 cells/mm2) and PBS-treated controls (n  8;
155.0  19.09 cells/mm2). Similarly, in situ hybridization for
Nkx2.2, showed no differences between the treatment groups
(Fig. 4e–h; PBS: n 5, 159.1 28.84 cells/mm2; Sema3A: n 7,
176.5 19.44 cells/mm2). Finally, the presence of apoptotic cells
was assessed by immunohistochemistry for activated caspase-3
(aCas3) and Nkx2.2. No differences were detected between
Sema3A- and PBS-infused animals (supplemental Fig. 4, avail-
able at www.jneurosci.org as supplemental material; total aCas
cells: 10 d: n 3; 55.50 12.84 cells/mm2; PBS: n 5; 84.46
11.45 cells/mm2; Sema3A: n  5; 82.68  11.45 cells/mm2;
aCas3/Nkx2.2 cells:10 d: n 3; 32.50 5.08 cells/mm2 PBS:
n  5; 27.09  3.73 cells/mm2; Sema3A: n  5; 32.21.5  3.0
cells/mm2).
Sema3A inhibits the lineage progression of OPCs in
demyelinated lesions
To assess OPC differentiation in situ hybridization for PLP was
conducted (Fig. 4i–l). Sema3A infusion significantly decreased
the density of PLP-positive cells in the lesions (n  7, 497.3 
127.9 cells/mm2) compared with PBS-infused controls (n  7,
911.0 112.3 cells/mm2). Levels of PLP-positiveOLCs following
infusion of Sema3A infusion were comparable to those found in
10 d controls (n  9, 506.4  75.40 cells/mm2), a time point at
Figure 3. a–d, Sema3A infusion did not alter the presence of MSR-B macrophages. e–h, Furthermore, Oil Red O staining did not show any differences in the phagocytic activity between
Sema3A-infused and control animals. Scale bar (in h): b–d, 50m; f–h, 30m.
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which lesions displayminimal amounts of remyelination indicating
that differentiation was inhibited. On the contrary, the number of
PLP-positive OLCs was significantly increased in PBS-controls at
28d (Fig. 4i; one-wayANOVA:p0.0109;Dunnett 10dvsPBSand
Sema3A: p 0.05).
To confirm that Sema3A induces a differentiation block in
OPCs immunolabeling for CC1, a marker of mature oligoden-
drocytes, was conducted (Fig. 4m–p; one-way ANOVA: p 
0.0001; Dunnett’s post test 10 d vs PBS and Sema3A: p  0.05).
The number of CC1/Olig2 cells increased significantly in
PBS-treated animals (n  4, 328.9  27.1 cells/mm2) at day 28
compared with the 10 d group (n  6, 101.8.9  14.71 cells/
mm2). This increase was absent in Sema3A-treated animals
where the levels of CC1/Olig2 cells remained comparable to
the levels detected in the 10 d group (n  4, 102.5  6.245
cells/mm2).
Sema3A inhibits CNS remyelination
Finally, the extent of remyelination was assessed 28 d post-lesion
induction on semithin resin sections (Fig. 5a–d). While remyeli-
nation in control animals was almost complete with the majority
of axons being surrounded by thin myelin sheaths (Blakemore,
1974), in Sema3A-infused lesions the large majority of axons
remained demyelinated. Where remyelination occurred, it
was confined to the border of the lesion. Remyelination was
compared between the groups by investigator-blinded rank
analysis (Kotter et al., 2006). The results confirm a strong
impairment of remyelination (Mann–WhitneyU: p 0.0005)
Figure 4. a–d, In situ hybridization for PDGFR- showed comparable OPC densities within lesions of Sema3A-treated animals and controls 28 d after lesion induction. e–h, Similarly, levels of Nkx2.2-
positive cells, amarker of OPC activation, were comparable in both experimental groups at 28 d. i–l, Assessment of OPC differentiation on the basis of ISH for PLP demonstrated a significant reduction of OPC
differentiationinSema3A-infusedlesions.m–p,ThesefindingswereconfirmedbyquantificationofCC1/Olig2-immunopositivematureoligodendrocytes inthelesion.Scalebar(inp):b–l,50m;n–p,30m.
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in Sema3A-infused animals (n  8;
mean rank value 11  3.207) compared
with controls (n  10; mean rank value
19.10  3.665). It is important to note
that Sema3A infusion does not affect the
integrity of mature myelin sheaths as
has been demonstrated by administra-
tion of Sema3A into naive CCPs (sup-
plemental Fig. 2c, available at www.
jneurosci.org as supplementalmaterial).
Sema3A arrests OPCs at a
premyelinating state
To confirm the light microscopic observa-
tions and for further descriptive studies the
samples were assessed by electron micros-
copy (Fig. 5e,f). As expected most axons in
PBS-infused lesions were surrounded by
thinmyelin sheaths,whichare characteristic
of remyelinationmediated by oligodendro-
cytes. Schwann cell-mediated remyelina-
tion, which is characterized by thicker
myelin sheaths thatoftenareassociatedwith
a nucleus resulting in the appearance of a
signet ring, was also occasionally observed.
In contrast, in Sema3A-infused animals the
majority of axons remained denuded. Al-
though a proportion of axons were con-
tactedbycellularprocesses resembling those
of oligodendrocytes, these failed to form
new compactmyelin sheaths. The bulk ofmyelin debris in Sema3A-
treated animals was cleared and only occasionally structures remi-
niscent of myelin debris were found.
Discussion
Numerous experiments have demonstrated that remyelination is
a reliable regenerative response of the adult CNS and that signif-
icant experimental manipulations are required to induce even a
transient impairment ofmyelin regeneration in vivo. In search for
an explanation for the discrepancies between efficient remyelina-
tion in experimental models and inefficient remyelination in hu-
man disease, the concept has emerged that MS lesions contain
specific OPC differentiation-inhibiting factors. Possible candi-
dates include polysialylated neural cell adhesion molecule (PSA-
NCAM) (Charles et al., 2000, 2002), hyaluronan (Back et al.,
2005), Wnt (Fancy et al., 2009), and Notch-1 (Wang et al., 1998;
John et al., 2002; Zhang et al., 2009) as well as unknown mole-
cules in myelin debris (Kotter et al., 2006; Baer et al., 2009). To
identify further OPC-differentiation inhibitors potentially relevant
for the failure of remyelination in MS, we assessed the effects of a
numberofOLC-relatedproteins ondifferentiatingOPCs. Fromthis
Sema3A emerged as a potential candidate. Although Sema3A is not
considered amyelin protein per se it can be expressed in cells of the
oligodendrocyte lineage (Williams et al., 2007).
Expression of Sema3A and NP1 in remyelinating lesions
To confirm endogenous Sema3A expression in the CCPmodel in
situ hybridization was conducted. As previously (Williams et al.,
2007), several sources of Sema3A were detected, including astro-
cytes, microglia/macrophages, and in a subpopulation of cells of
the oligodendrocyte lineage. While Sema3A transcripts often co-
localized with low-Olig-2-expressing cells Sema3A mRNA could
not be detected in high-Olig-2-expressing cells. Differences in
Olig-2 expression are thought to discriminate between activated
and quiescentOPCpopulation in remyelinating lesions (Fancy et
al., 2004). Detection of Sema3AmRNA in low-Olig-2-expressing
OPCs may therefore indicate that Sema3A expression is specific
to earlier ormore quiescentOPC stages where it could potentially
function as a regulator of OPC density.
In addition expression of the semaphorin receptor NP-1 was
assessed. As suggested by previous studies (Williams et al., 2007)
NP-1 is expressed byOPCs in culture and following experimental
demyelination, thus confirming the ability ofOPCs to react to the
presence of Sema3A. Furthermore, NP-1 expressionwas noted in
astrocytes and cells of the macrophages/microglia lineage. NP-1-
expressingmacrophages/microglia appeared to be smaller and to
express OPN at lower levels than NP-1-negative macrophages/
microglia. These differences in the expression of NP-1 may again
point to differences between different cellular states, e.g., phago-
cytotic macrophages versus earlier stages, or to cells from differ-
ent origins.
Class 3 semaphorins as regulators of OPC migration
On the basis that Sema3A exerts repulsive effects on OPCmigra-
tion it has been proposed that Sema3A prevents repopulation
of demyelinated lesions with remyelination-competent cells
(Spassky et al., 2002). However, OPCs are commonly present in
MS lesions and thus expression of Sema3A does not generally
prevent their recruitment into areas of demyelination (Wolswijk,
1998, 2000; Chang et al., 2000, 2002; Kuhlmann et al., 2008). A
potential explanation for this discrepancy is provided by the fact
that anothermember of class 3 semaphorins, namely semaphorin
3F (Sema3F), is expressed in demyelinated lesions (Williams et
al., 2007). Sema3F has been recognized as a chemoattractant and
mitogenic factor for OPCs (Spassky et al., 2002). Similar to
Sema3A, Sema3F expression is restricted to active MS plaques
and not found in chronic MS lesions or normal white matter.
Figure 5. a, The extent of remyelination was assessed by rank analysis of methylene blue and Azur-II-stained semithin-
sections. b–d, Sema3A infusion induced a highly significant reduction of remyelination compared with PBS controls. Whereas
remyelination in controls was nearly complete 28 d post-lesion induction (b), the majority of axons in Sema3A-infused lesions
remained demyelinated (c), resembling lesions at 10 d before Sema3A infusion (d). e, EM analysis used to establish the stage at
which remyelination was arrested confirmed that most axons in control lesions were remyelinated by oligodendrocytes (black
arrowheads). f, Although axons of Sema3A-treated animals were abundant and intact on electron micrographs they remained
demyelinated (stars). Some axons were contacted by cellular processes that were arrested at a premyelinating state and failed to
produce compacted myelin (outline arrowhead). Scale bar (in f ): b–d, 30m; e, f, 1m.
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However, important differences with respect to the expression of
Sema3A and Sema3F have been identified as increased levels of
Sema3F expression were found in highly inflammatory lesions,
where CD68-positive cells represent 15% of the perilesional
cells. In contrast, the highest levels of Sema3A expression were
associatedwith lower levels of inflammation. These findings suggest
that while attractive cues may dominate in early inflammatory le-
sions these give way to aversive cues during later stages. Conversely,
if the recruitment or differentiation of OPCs at early stages is insuf-
ficient, a dysbalance favoring Sema3A expression may have the po-
tential to interfere with both OPC recruitment and differentiation
and thus contribute to remyelination failure inMS.
Sema3A as an inhibitor of OPC differentiation
Earlier studies suggest that Sema3A induces a reversible reduc-
tion of process complexity in adult OLCs (Ricard et al., 2001) and
causes redirection of OLC growth cones away from Sema3A
(Cohen et al., 2003). Our finding that the presence of Sema3A is
able to inhibit the differentiation of OPCs in vitro prompted us to
ask whether Sema3A is able to exert a similar effect in remyeli-
nating lesions. Infusion of recombinant Sema3A 10 d after exper-
imental lesioning induced a failure of CNS remyelination that
was associated with an inhibition of OPC differentiation.
The levels of Sema3A present in demyelinating lesions are
unknown and it is therefore not possible to assess how the
amount of Sema3A infused compares with levels present in MS
lesions. However, infusion of Sema3A in the present series of
experiments did not reach toxic levels as first, Sema3A did not
influence the lesion size, second no differences were detected in
the numbers of macrophages, OPCs and the level of apoptotic
cells in the lesions, and third, infusion of Sema3A into normal
white matter at the same concentration did not induce any de-
tectable abnormalities.
The results of ourmonoculture assay demonstrate a direct and
specific effect of Sema3AonOPCdifferentiation.However, as the
pool ofmature oligodendrocytes increases strongly during remy-
elination and as this might require the recruitment of additional
OPCs, Sema3Amay potentially affect the recruitment of OPCs at
late stages. Although our in vitro findings seem to translate di-
rectly into the situation in vivo it is possible that Sema3A exerts
additional indirect effects on OPCs in remyelinating lesions.
Sema3A is known to induce a variety of cellular responses includ-
ing apoptosis, redirection of processes, and exerting negative
guidance cues in diverse cell types such as astrocytes,macrophage
lineage cells, and neurons (Pasterkamp et al., 1998; De Winter et
al., 2002; Spassky et al., 2002; Zhou et al., 2008; Ji et al., 2009).
The physiologic function of Sema3A in OPCs remains specu-
lative. Sema3A secreted by axons, macrophages or OPCs them-
selvesmay provide aversive guidance cues, which help to regulate
the number of OPCs in a certain area. Furthermore, the inhibi-
tory effects of Sema3A on OPC differentiation may be part of a
regulatorymechanism signaling that anOPChas already engaged
with a certain stretch of an axon and prevent further OPCs from
attempting to form a myelin sheath at the same location.
Sema3A is expressed at critical stages of demyelination
in disease
Whereas expression of the known OPC differentiation inhibitors
PSA-NCAM(Charles et al., 2000, 2002) andhyaluronan (Back et al.,
2005) in MS lesions is associated with chronic stages of demyelina-
tion, similar toNotch-1 (John et al., 2002), upregulation of Sema3A
transcripts was detected in late active MS lesions (Williams et al.,
2007). At this stage the presence of cells capable of reacting to
Sema3A, as judged by their expression of the Sema3A receptors
neuropilin-1 and2, is restricted to theplaque andperiplaque area. In
contrast neuropilin-1/2-positive cells seem to be absent in normal
appearing whitematter. On the basis that remyelination inMS pro-
ceeds in a similarway as experimental remyelination, Sema3Aseems
to be expressed at a critical stage, at which OPCs recruited into de-
myelinated lesions may be prevented from differentiating into my-
elin forming oligodendrocytes.
Semaphorin signaling as a potential target for promoting
CNS remyelination
The context in which Sema3A is expressed in MS together with
the finding that Sema3A is able to inhibit CNS remyelination in
vivo, implies that Sema3A signaling may be a relevant target for
promoting remyelination in demyelinating disease. There are
several levels at which this could be achieved. These include
antibody-mediated neutralization of Sema3A epitopes or phar-
macological modulation of down-stream signaling effectors. A
number of drugs that are able to modulate signaling effectors of
Sema3A including RhoA (Baer et al., 2009) are currently being
used or clinically evaluated for the treatment of other diseases
such as cancer. It will be important to establish their efficacy to
promote remyelination in preclinical models of remyelination.
Given the clinical availability of such drugs, a potential transla-
tion into clinical disease only seems a small step ahead.
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